SCHEMBL375120

SCHEMBL375120

CCc1cccc(-c2nc(C34CCC(C(N)=O)(CC3)CC4)[nH]c2-c2ccc3c(c2)OCO3)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 14/20 0.69
ACVR1B P36896 3/20 0.40
RIPK2 O43353 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 2/20 0.40
PRKD3 O94806 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
TGFBR2 P37173 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
CSNK1E P49674 1/20 0.40
RPS6KA1 Q15418 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376086 0.92 TGFBR1 (0.58) TGFBR1ACVR1BRIPK2TDP1KDM4E
SCHEMBL30194941 0.89 TGFBR1 (0.86) TGFBR1ACVR1BRIPK2TDP1KDM4E
SCHEMBL376161 0.89 TGFBR1 (0.86) TGFBR1ACVR1BRIPK2TDP1KDM4E
SCHEMBL4339710 0.81 TGFBR1 (1.00) TGFBR1ACVR1BRIPK2TDP1KDM4E
SCHEMBL29504100 0.81 TGFBR1 (1.00) TGFBR1ACVR1BRIPK2TDP1KDM4E
SCHEMBL15678349 0.80 TGFBR1 (0.73) TGFBR1ACVR1BRIPK2TDP1KDM4E
SCHEMBL375627 0.80 TGFBR1 (0.73) TGFBR1ACVR1BRIPK2TDP1KDM4E
SCHEMBL4347711 0.78 TGFBR1 (0.70) TGFBR1ACVR1BRIPK2TDP1KDM4E
SCHEMBL4337372 0.78 TGFBR1 (0.69) TGFBR1ACVR1BRIPK2TDP1MAPK14
SCHEMBL4351457 0.77 TGFBR1 (0.56) TGFBR1ACVR1BRIPK2TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871744-B2 Compounds and methods for selectively targeting tumor-associated mucins B & G Partyers, LLC (US) 2014-10-28 US claimed
US-8871744-B2 Compounds and methods for selectively targeting tumor-associated mucins B & G Partyers, LLC (US) 2014-10-28 US disclosed
US-20120022016-A1 Compounds and methods for selectively targeting tumor-associated mucins B&G PARTNERS, LLC 2012-01-26 US disclosed
EP-2409708-A1 Compounds and methods for selectively targeting tumor-associated mucins B & G Partners, LLC (US) 2012-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022016-A1 Compounds and methods for selectively targeting tumor-associated mucins MUC1, NEU4, ALK TGFBR1 1324/4885ACVR1B 205/4885RIPK2 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.